The uncertain benefit from implantable cardioverter-defibrillators in nonischemic cardiomyopathy: How to guide clinical decision-making?

Authors

Mohsin Khan, Advocate Aurora HealthFollow
Arshad Jahangir, Advocate Aurora HealthFollow

Recommended Citation

Khan M, Jahangir A. The Uncertain Benefit from Implantable Cardioverter-Defibrillators in Nonischemic Cardiomyopathy: How to Guide Clinical Decision-Making?. Cardiol Clin. 2023;41(4):545-555. doi:10.1016/j.ccl.2023.06.005

Affiliations

Aurora Sinai/Aurora St. Luke's Medical Centers

Abstract

Life-threatening dysrhythmias remain a significant cause of mortality in patients with nonischemic cardiomyopathy (NICM). Implantable cardioverter-defibrillators (ICD) effectively reduce mortality in patients who have survived a life-threatening arrhythmic event. The evidence for survival benefit of primary prevention ICD for patients with high-risk NICM on guideline-directed medical therapy is not as robust, with efficacy questioned by recent studies. In this review, we summarize the data on the risk of life-threatening arrhythmias in NICM, the recommendations, and the evidence supporting the efficacy of primary prevention ICD, and highlight tools that may improve the identification of patients who could benefit from primary prevention ICD implantation.

Type

Article

PubMed ID

37743077